[18F] JNJ-64326067 的临床评价:一种用于检测阿尔茨海默病 tau 蛋白病理的新型候选 PET 示踪剂
这项概念验证研究比较了 5 例 [18F]-florbetapir PET 淀粉样蛋白阳性的很可能阿尔茨海默病(AD)患者与 5 例年龄匹配的健康对照,并估算 [18F] JNJ-64326067 的全身剂量学。结果显示 5 例 AD 患者中 4 例在相关皮质区域出现视觉可见的示踪剂滞留,健康对照中 4 例无脑内 tau 信号。全身有效剂量估计为女性 0.0257 mSv/MBq、男性 0.0254 mSv/MBq。
要点
- 5 例很可能 AD 患者中 4 例视觉可见 [18F] JNJ-64326067 在相关皮质区域滞留。
- 健康对照中 4 例无脑内 tau 信号,1 例因青少年枪伤处出现局灶信号。
- 视觉阳性受试者皮质信号在 120 分钟时接近稳态。
核心结论
- [18F] JNJ-64326067 可能有助于 tau 聚集的检测和定量。
研究设计与样本
- 前后获取 90 分钟及 120 至 180 分钟的 [18F] JNJ-64326067 PET 扫描,纳入 5 例 [18F]-florbetapir PET 淀粉样蛋白阳性的很可能 AD 患者(73 ± 9 岁)和 5 例 [18F]-florbetapir PET 淀粉样蛋白阴性的健康对照(71 ± 7 岁)。
- 对 6 名健康受试者分 3 次扫描共 5.5 小时获取全身 [18F] JNJ-64326067 PET CT 扫描以进行剂量学估算。
- 脑 PET 扫描进行视觉审阅,区域定量包括 Logan 图形分析估算的分布容积比(DVR)和晚期帧静态 SUVr 分析,均以腹侧小脑皮质为参考区。
主要发现
- 5 例 AD 受试者中 4 例在相关皮质区域视觉可见 [18F] JNJ-64326067 滞留,1 例视觉阴性。
- 健康对照中 4 例无脑内 tau 信号,1 例在青少年枪伤部位下方的枕叶和顶叶皮质出现局灶 PET 信号。
- 视觉阳性受试者皮质信号在 120 分钟时接近稳态。
- 视觉阳性 AD 受试者颞叶和额叶皮质 SUVr/DVR 分别为 1.21 至 3.09/1.2 至 2.18,健康对照分别为 0.92 至 1.28/0.91 至 1.16。
- 全身有效剂量估计为女性 0.0257 mSv/MBq、男性 0.0254 mSv/MBq。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The accumulation of misfolded tau is a common feature of several neurodegenerative disorders, with Alzheimer's disease (AD) being the most common. Earlier we identified JNJ-64326067, a novel isoquinoline derivative with high affinity and selectivity for tau aggregates from human AD brain. We report the dosimetry of [18F] JNJ-64326067 and results of a proof-of-concept study comparing subjects with probable Alzheimer's disease to age-matched healthy controls. METHODS: [18F] JNJ-64326067 PET scans were acquired for 90 min and then from 120 to 180 min in 5 participants with [18F]-florbetapir PET amyloid positive probable AD (73 ± 9 years) and 5 [18F]-florbetapir PET amyloid negative healthy controls (71 ± 7 years). Whole-body [18F] JNJ-64326067 PET CT scans were acquired in six healthy subjects for 5.5 h in 3 scanning sessions. Brain PET scans were visually reviewed. Regional quantification included kinetic analysis of distribution volume ration (DVR) estimated by Logan graphical analysis over the entire scan and static analysis of SUVr in late frames. Both methods used ventral cerebellar cortex as a reference region. RESULTS: One of the healthy controls had focal areas of PET signal in occipital and parietal cortex underlying the site of a gunshot injury as an adolescent; the other four healthy subjects had no tau brain signal. Four of the 5 AD participants had visually apparent retention of [18F] JNJ-64326067 in relevant cortical regions. One of the AD subjects was visually negative. Cortical signal in visually positive subjects approached steady state by 120 min. Temporal and frontal cortical SUVr/DVR values in visually positive AD subjects ranged from 1.21 to 3.09/1.2 to 2.18 and from 0.92 to 1.28/0.91 to 1.16 in healthy controls. Whole-body effective dose was estimated to be 0.0257 mSv/MBq for females and 0.0254 mSv/MBq for males. CONCLUSIONS: [18F] JNJ-64326067 could be useful for detection and quantitation of tau aggregates.
引用
- Schmidt ME, Janssens L, Moechars D, et al. Clinical evaluation of [18F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2020. PMID: 32535652. doi:10.1007/s00259-020-04880-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。